Transforming clinical trials with scalable immune monitoring approaches

Tuesday, November 11, at 15:00 GMT | 16:00 CET | 10:00 EST | 7:00 PST

The development of effective therapeutics relies on high-quality immune phenotyping data collected in clinical trials. Yet, traditional approaches to longitudinal immune monitoring are limited by complex logistics, strict sample-handling requirements and reagent stability issues. These factors can compromise data quality and limit access to geographically dispersed centers.

In this webinar, Helen McGuire, Ph.D., will present a simplified workflow for executing a large-scale immune monitoring strategy, built on a 50-plex lyophilized CyTOF™ assay. She will discuss how this approach enabled her team to expand the implementation of their novel​ proteomic immune signature of lung cancer​ nonresponsiveness to remote settings, allowing access to underrepresented populations. This scalable workflow opens the door for broader site collection, transforming multi-site clinical studies with standardizing reagents to enable consistent and reproducible data across diverse trial centers.

This webinar will discuss:

• Immune monitoring for improved cancer prognosis: A novel immune signature that robustly predicts failure to make a clinical response to checkpoint therapies targeting the PD-1/PD-L1 pathway in melanoma and lung cancer
• Standardized immune monitoring with LyoMax™ CyTOF Panels: How dried-down antibody panels, enabled through Custom Lyophilization Service, reduce variability and streamline workflows. This workflow, unique to mass cytometry, enables large-scale immune monitoring while minimizing technical variation via sample barcoding and freezing of stained samples for shipment to a central site for batch acquisition.

Key learning objectives:

• Understand how a novel immune signature can predict clinical nonresponse to checkpoint inhibitors in cancer.
• Gain practical insights into implementing large-scale immune monitoring workflows with standardized, lyophilized CyTOF panels.
• Discover how to minimize technical variation and optimize multi-site sample acquisition for reliable, reproducible data.

Who should attend?

Immunologists, clinical researchers, laboratory directors, translational scientists, and anyone involved in multi-site clinical trials or immune monitoring studies.

Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.